← Back to patent-cliff list
Glucagon intranasal (Eli Lilly/Locemia Solutions)
Tier C — Watch / tradeGlucagon intranasal (Eli Lilly/Locemia Solutions)
Amg Medical
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GCGR
Brand：Baqsimi
Indications (approved)：Hypoglycaemia
Regional status
US
Approved
2019-07-24
EU
Approved
2019-12-16
China
Approved
2024-06-04
Japan
No progress
2018-02-21
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Glucagon intranasal (Eli Lilly/Locemia Solutions)?
Approved indications include: Hypoglycaemia.
When does the Glucagon intranasal (Eli Lilly/Locemia Solutions) patent expire?
No public expiry year is available for Glucagon intranasal (Eli Lilly/Locemia Solutions) yet; this page updates once verified.
How do I get a quote for Glucagon intranasal (Eli Lilly/Locemia Solutions) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29